Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

There was a significant association between 25-hydroxyvitamin D levels and presentation in DKA; each one-unit increase in 25-hydroxyvitamin D was associated with a 6% decrease in the odds of presenting in DKA (OR: 0.94, 95% CI: 0.89-0.99, p=0.03). 25-hydroxyvitamin D levels were significantly associated with DKA severity (p=0.01), with lower levels observed in patients with more severe DKA.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were diagnosed at our pediatric endocrinology practice at Northwell Health between June 2023 and February 2025.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

25-hydroxyvitamin D and the initial presentation of pediatric type 1 diabetes: associations with ketoacidosis severity and beta-cell function

Study design awaiting verification · Frontiers in Endocrinology · 2026

Original publication title

25-hydroxyvitamin D and the initial presentation of pediatric type 1 diabetes: associations with ketoacidosis severity and beta-cell function

Sofya Ilmer; Rubab Sohail; Sharon Hyman

Copyright © 2026 Ilmer, Sohail and Hyman.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In this retrospective chart review of children newly diagnosed with T1DM, we found a significant association between 25-hydroxyvitamin D levels and DKA severity. Higher 25-hydroxyvitamin D levels correlated with less severe acidosis and lower odds of DKA presentation. This suggests a potential protective role of 25-hydroxyvitamin D against severe metabolic decompensation at T1DM onset. However, we found no significant association between 25-hydroxyvitamin D and markers of β-cell function or glycemic control at diagnosis. Further prospective studies are needed to confirm these findings, investigate the underlying mechanisms, and explore the potential clinical implications of optimizing 25-hydroxyvitamin D status in children at risk for or newly diagnosed with T1DM.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by pancreatic β-cell destruction and absolute insulin deficiency, with a rising global incidence that has prompted investigation into modifiable environmental influences such as 25-hydroxyvitamin D on disease risk and presentation (1, 2). Beyond its role in calcium homeostasis, 25-hydroxyvitamin D exerts immunomodulatory and anti-inflammatory effects that may be relevant to T1DM pathogenesis (1, 3). A high prevalence of 25-hydroxyvitamin D deficiency is reported in children with T1DM, but the link to T1DM development remains complex; some studies suggest early-life 25-hydroxyvitamin D sufficiency may be protective, while others find no clear association (3Not reported5).

At diagnosis, lower 25-hydroxyvitamin D is linked to increased DKA severity and poorer metabolic control including higher HbA1c and increased insulin needs (4, 6, 7). Children with DKA often have lower 25-hydroxyvitamin D levels, and acidosis severity correlates inversely with 25-hydroxyvitamin D status (6Not reported9). The relationship between 25-hydroxyvitamin D and β-cell function at diagnosis (measured by C-peptide and insulin) is less established. Some studies report associations with lower 25-hydroxyvitamin D and reduced C-peptide or higher insulin requirements, but interventional trials on vitamin D supplementation show inconsistent benefits (1, 10Not reported14).

This study examines the associations between 25-hydroxyvitamin D levels, the presence or absence of DKA as well as both DKA severity and markers of β-cell function (insulin and C-peptide) in newly diagnosed pediatric T1DM. Improved understanding of these relationships could inform risk stratification at presentation, guide early management strategies, and potentially support targeted interventions to optimize metabolic outcomes and preserve beta-cell function in this vulnerable population.

Source: Introduction

Study methods

What methods does the paper describe?

Study design and population

This retrospective chart review included patients under the age of 18 years diagnosed with type 1 diabetes mellitus (T1DM) at Cohen Children’s Medical Center between June 2023 and February 2025. Patients were identified using an encrypted nursing log maintained at our Pediatric Endocrinology practice at Northwell Health in New Hyde Park, New York, which tracks all patients with newly diagnosed diabetes for diabetes education purposes. This log was used to identify potential T1DM cases. Patients with suspected type 2 diabetes were not included in the study. 146 patients with type 1 diabetes were identified.

Among them 43 patients without a documented 25-hydroxyvitamin D level within two days of presentation were excluded from data collection. 4 patients with suspected type 1 diabetes were also excluded due to the absence of diabetes autoantibodies. 99 patients with type 1 diabetes based on clinical presentation and at least one positive antibody were included in the study. The study aimed to investigate: 1) the association between 25-hydroxyvitamin D levels and initial presentation (presence or absence of DKA) as well as DKA severity at presentation (based on pH, bicarbonate and beta hydroxybutyrate levels); 2) the relationship between 25-hydroxyvitamin D levels and HbA1c at diagnosis; and 3) the relationship between 25-hydroxyvitamin D levels and markers of beta-cell function (insulin and C-peptide levels) at diagnosis.

Measurement of 25-hydroxyvitamin D is a standard component of the initial laboratory evaluation for new-onset T1DM at our institution. For this study, the inclusion criterion of a measurement within two days of presentation was established to ensure the level accurately reflected the patient’s status at the time of acute metabolic presentation.

Data collection

Demographic data (age, sex, race, ethnicity, language spoken, insurance status, weight, height for calculation of BMI z-scores and BMI z-scores), 25-hydroxyvitamin D levels, and clinical presentation data were extracted from the electronic health record (EHR) for all patients. 25-hydroxyvitamin D levels, measured at or around the time of T1DM diagnosis, were categorized as sufficient (>30 ng/mL), insufficient (20 to 30 ng/mL), and deficient (<20 ng/mL) for analysis. Clinical and biochemical presentation data included duration of symptoms, Hemoglobin A1c, diabetes autoantibody results, pH, bicarbonate, c-peptide levels, beta-hydroxybutyrate (BHB) levels, and the presence or absence of DKA.

DKA severity was categorized as mild (pH 7.2-7.29), moderate (pH 7.1-7.19), or severe (pH < 7.1) based on pH levels at presentation. Beta-cell function was assessed using insulin and C-peptide levels. Insulin levels drawn after the documented initiation of an intravenous insulin drip were excluded to avoid confounding from exogenous insulin. The timing and administration of potential subcutaneous insulin given prior to the drip could not be reliably determined retrospectively. Diabetes antibody testing included glutamic acid decarboxylase antibody (GAD), zinc transporter 8 antibody (ZnT8), islet cell antibody (ICA), islet IA-2 antigen antibody (IA-2) and insulin antibody.

Data analysis

Frequencies and proportions were calculated for categorical variables and means ± standard deviation (SD) or medians and interquartile ranges (IQR; Q1-Q3) were calculated for continuous variables, as appropriate. Univariate analyses were performed to compare demographic and clinical characteristics based on 25-hydroxyvitamin D levels (sufficient, insufficient, or deficient) using the Kruskal-Wallis test or ANOVA for continuous variables, and the Chi-square test or Fisher’s exact test for categorical variables, as appropriate. The Spearman rank correlation coefficient was reported between 25-hydroxyvitamin D levels and all continuous variables, along with the partial correlation coefficient adjusting for race, ethnicity, and insurance status.

Cohen’s guidelines were used to interpret the strength of the correlation. Multivariable logistic regression was utilized to evaluate the association between 25-hydroxyvitamin D levels and presentation in DKA, adjusting for race, ethnicity, and insurance status. The covariates were specified a priori. All analyses were conducted using available data and p-values < 0.05 were considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Source: Materials and methods Source: Materials and methods Source: Materials and methods

Abstract: Discussion

These findings suggest a potential protective role of 25-hydroxyvitamin D against severe metabolic decompensation at T1DM onset, specifically relating to DKA, but not beta-cell function. Further research is needed to confirm these findings and explore the potential mechanisms and clinical implications.

Source: Discussion

Discussion

Our study investigated the relationship between 25-hydroxyvitamin D levels and the acuity of presentation and β-cell function in children newly diagnosed with type 1 diabetes. Our primary finding indicates a significant association between 25-hydroxyvitamin D levels and DKA presentation and severity. Higher 25-hydroxyvitamin D levels were associated with lower odds of DKA and less severe acidosis, as evidenced by the positive correlations with pH and bicarbonate, and the negative correlation with BHB. These findings persisted after adjusting for potential confounders, suggesting that 25-hydroxyvitamin D may play a protective role against severe metabolic decompensation at the onset of T1DM.

A critical consideration when interpreting our findings is the bidirectional relationship between acidosis and measured 25-hydroxyvitamin D levels, which complicates the determination of causality. While our data demonstrates that lower 25-hydroxyvitamin D levels are associated with more severe DKA, acidosis itself can transiently suppress measured 25-hydroxyvitamin D concentrations through multiple mechanisms (15, 16). Acute metabolic acidosis decreases 1-alpha-hydroxylase activity and increases 24-hydroxylase activity in the kidney, thereby reducing conversion of 25-hydroxyvitamin D to its active form (17).

Additionally, acidosis reduces vitamin D-binding protein (VDBP) levels, which in turn lowers total circulating 25-hydroxyvitamin D concentrations (6). Studies have shown that 25-hydroxyvitamin D levels increase by an average of 5 ng/mL following resolution of acidosis in children with new-onset T1DM, with bicarbonate levels correlating more strongly with 25-hydroxyvitamin D than pH (15, 16, 18). However, the persistence of low 25-hydroxyvitamin D levels after acidosis resolution in many patients suggests that true 25-hydroxyvitamin D deficiency, rather than solely acidosis-induced suppression, contributes to DKA severity (15).

This creates a potential vicious cycle: pre-existing 25-hydroxyvitamin D deficiency may predispose to more severe metabolic decompensation, while the resulting acidosis further suppresses measured 25-hydroxyvitamin D levels, exaggerating the apparent deficiency. Our study cannot definitively distinguish whether the observed low 25-hydroxyvitamin D levels represent chronic deficiency that contributed to DKA development, acute acidosis-induced suppression of 25-hydroxyvitamin D metabolism, or a combination of both mechanisms. Future prospective studies measuring 25-hydroxyvitamin D levels both at presentation and after complete metabolic stabilization, along with assessment of free and bioavailable 25-hydroxyvitamin D fractions, would help clarify this relationship.

This potential link between deficiency and DKA is biologically plausible, as our results align with previous research, suggesting a link between 25-hydroxyvitamin D deficiency and increased risk of autoimmune diseases, including T1DM (3, 6, 19). 25-hydroxyvitamin D has immunomodulatory properties, and its deficiency could contribute to a more aggressive autoimmune response, potentially leading to a more severe presentation of T1DM with DKA. There are several proposed mechanisms for this. First, 25-hydroxyvitamin D plays a role in modulating immune responses and inflammation.

Deficiency is linked to increased pro-inflammatory cytokine production (e.g., IFN-γ, TNF-α, IL-6, IL-1β), which may exacerbate the autoimmune destruction of pancreatic beta cells, leading to more rapid and severe insulin deficiency and thus more severe DKA at presentation (3, 4, 6, 20). This pathway is primarily about immune-mediated beta cell loss, not insulin resistance. Second, 25-hydroxyvitamin D deficiency in itself is linked to increased systemic inflammation, evidenced by higher circulating pro-inflammatory cytokines. This increased inflammatory state may worsen insulin resistance and accelerate the beta cell loss, leading to more severe DKA.

This mechanism is more about metabolic stress and insulin resistance, rather than direct autoimmune beta cell destruction. Finally, 25-hydroxyvitamin D is involved in maintaining calcium and phosphate homeostasis, which can be disrupted during acidosis, leading to worsening metabolic derangements in DKA. Children with lower 25-hydroxyvitamin D levels at diagnosis have worse glycemic control and higher insulin requirements which are risk factors for severe DKA (18).

Contrary to our hypothesis, we did not find a significant association between 25-hydroxyvitamin D levels and HbA1c or markers of β-cell function (insulin and C-peptide). This suggests that 25-hydroxyvitamin D’s potential protective effect may be specific to metabolic acidosis at diagnosis rather than overall glycemic control or β-cell preservation. It’s important to note the significant amount of missing data for insulin and C-peptide levels, which could have limited our ability to detect a true association. Previous studies have reported conflicting results, with some showing weak or short-term associations between 25-hydroxyvitamin D and glycemic markers, while others found no significant relationship, highlighting the diversity in study design, population, and timing of measurements (4, 21, 22).

This is consistent with currently published medical literature, which shows that 25-hydroxyvitamin D status at diagnosis does not reliably correlate with glycemic control or beta-cell reserve.

Our study also revealed significant associations between 25-hydroxyvitamin D levels and race. The observed disparity in 25-hydroxyvitamin D levels among racial and ethnic groups is primarily attributable to differences in skin pigmentation, genetic polymorphisms affecting 25-hydroxyvitamin D metabolism (23), and social determinants of health. Individuals with darker skin have higher melanin content, which reduces the skin’s ability to synthesize 25-hydroxyvitamin D from sunlight exposure. Melanin interferes with endogenous 25-hydroxyvitamin D production, leading to a higher prevalence of deficiency in these populations compared to White or Caucasian individuals, who generally have lighter skin and greater cutaneous vitamin D synthesis (24).

The significant correlation of 25-hydroxyvitamin D deficiency in patients receiving government assistance (Medicaid) compared to those with commercial insurance is likely related to socioeconomic factors such as reduced access to healthcare, delayed presentation for medical evaluation, and limited access to vitamin D-rich foods. Lower household income and food insecurity are associated with poorer diet quality and lower intake of vitamin D, while reduced healthcare access can delay both diagnosis and preventive care, increasing the risk of deficiency and more severe diabetic ketoacidosis at onset (24, 25).

Further research is warranted to explore these associations and potential disparities in 25-hydroxyvitamin D levels among different patient subgroups.

Our study showed an association between 25-hydroxyvitamin D levels and the presence of islet cell antibodies. This association was not found with other antibodies such as GAD, IA-2, ZnT8 and insulin antibodies. Islet cell antibodies (ICA) reflect a broad immune response against multiple islet cell antigens and are less specific than autoantibodies directed against defined antigens such as GAD, IA-2, ZnT8, or insulin. ICA positivity may indicate an earlier or more active stage of islet autoimmunity, and 25-hydroxyvitamin D deficiency: through its immunomodulatory effects: may preferentially influence the development of these broad-spectrum islet cell antibodies (2).

There is no evidence in literature to suggest there may be cross reactivity between these two assays (ICA and 25-hydroxyvitamin D).

Several limitations should be considered. The retrospective design introduces the potential for selection bias and limits our ability to establish causality. The relatively small sample size, especially for the analyses involving insulin and C-peptide, may have reduced statistical power. Specifically for the beta-cell function analysis, the significant amount of missing data for insulin and C-peptide, and the lack of systematically recorded concurrent glucose levels, limit the interpretation of these markers. Furthermore, 25-hydroxyvitamin D levels were measured at a single time point, which may not reflect long-term 25-hydroxyvitamin D status.

Importantly, acidosis at diagnosis can transiently lower serum 25-hydroxyvitamin D concentrations in type 1 diabetes patients, exaggerating differences with controls; adjusting for acidosis attenuates this effect (10). Additionally, due to the retrospective design, we could not account for a prior history of 25-hydroxyvitamin D deficiency or supplementation, which could have influenced the baseline levels observed at presentation. Finally, we did not systematically collect data on co-existing acute illnesses (e.g., infections), which could have independently influenced the severity of DKA at presentation.

Despite these limitations, our study provides valuable insights into the relationship between 25-hydroxyvitamin D and T1DM presentation. The association between 25-hydroxyvitamin D deficiency and DKA severity warrants further investigation in larger prospective studies. Future research should explore the mechanisms linking 25-hydroxyvitamin D and DKA, as well as the potential benefits of vitamin D supplementation in preventing severe metabolic complications in newly diagnosed T1DM patients. Additionally, studies should investigate the impact of socioeconomic factors and access to care on 25-hydroxyvitamin D levels in children at risk for T1DM.

Our findings suggest that optimizing 25-hydroxyvitamin D levels in children might be a potential avenue for mitigating the severity of T1DM presentation.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

The baseline demographic and clinical characteristics of the 99 participants are summarized in Table 1. Demographic characteristics included a mean ± SD age of 10.3 ± 4.4 years, with 50.5% (n=50) female. Racial distribution was 21.2% Black (n=21), 40.4% (n=40) Asian/Native Hawaiian/Other, 38.4% (n=38) White, and the majority (70.7%, n=70) were not Hispanic or Latino. 55.6% (n=55) of all patients had commercial insurance. At presentation, 53.5% were in DKA (n=53), with a mean ± SD HbA1c of 11.9 ± 2.2%.

The median 25-hydroxyvitamin D level was 20.5 (IQR 16.0-28.8) ng/mL, and 44.4%(n=44) were 25-hydroxyvitamin D deficient (<20 ng/mL).

Table 1

Baseline demographic and clinical characteristics of subjects by 25-hydroxyvitamin D status.

VariableOverall (n=99)Deficient (<20 ng/mL) (n=44)Insufficient (20 to 30 ng/mL) (n=33)Sufficient (>30 ng/mL) (n=22)p value
Age, years (mean ± SD) 10.3 ± 4.410.3 ± 3.99.9 ± 4.59.1 ± 5.10.60
Weight, kg (median [IQR]) 36.1 [24.6 to 49.2]37.6 [29.0 to 49.5]38.8 [24.6 to 47.0]31.4 [21.2 to 57.4]0.76
BMI Z-score (mean ± SD)† -0.35 ± 1.55-0.17 ± 1.86-0.22 ± 1.31-0.88 ± 1.100.20
Sex, n (%) 0.86
 Female50 (50.5)23 (52.3)17 (51.5)10 (45.5)
 Male49 (49.5)21 (47.7)16 (48.5)12 (54.6)
Race, n (%) 0.02
 White38 (38.4)9 (20.5)16 (48.5)13 (59.1)
 Black21 (21.2)11 (25.0)6 (18.2)4 (18.2)
 Asian/Native
 Hawaiian/Other
40 (40.4)24 (54.5)11 (33.3)5 (22.7)
Ethnicity, n (%) 0.45
 Hispanic or Latino19 (19.2)12 (27.3)5 (15.2)2 (9.1)
 Not Hispanic or Latino70 (70.7)28 (63.6)25 (75.8)17 (77.3)
 Unknown10 (10.1)4 (9.1)3 (9.1)3 (13.6)
Type of Insurance* 0.0008
 Commercial55 (55.6)15 (34.9)25 (75.8)15 (68.2)
 Medicaid43 (43.4)28 (65.1)8 (24.2)7 (31.8)
Presence of DKA 0.002
 Yes53 (53.5)32 (72.7)11 (33.3)10 (45.5)
 No46 (46.5)12(27.3)22 (66.7)12 (54.6)
Hemoglobin A1c, % (mean ± SD)  11.9 ± 2.212.2 ± 2.011.4 ± 2.412.2 ± 2.20.24
25(OH)D, ng/mL (median [IQR] 20.5 [16.0 to 28.8]15.8 [14.5 to 17.8]23.3 [21.4 to 27.5]35.4 [31.7 to 41.3] <.0001

*Only 1 patient was uninsured and was excluded from this comparison.

†Data available for 96 patients.

Bold values indicate statistical significance (p < 0.05).

25-hydroxyvitamin D levels were significantly associated with several factors. White patients were more likely to have sufficient 25-hydroxyvitamin D levels, while Black/Asian/Native Hawaiian/Other patients were more likely to be deficient (p=0.02); 25-hydroxyvitamin D levels were significantly lower in patients with Medicaid compared to those with commercial insurance (p=0.0008). Patients presenting with DKA had significantly lower 25-hydroxyvitamin D levels (p=0.002), 72.7% of deficient patients presented in DKA, compared to 33.3% of insufficient and 45.5% of sufficient patients. No significant associations were found between 25-hydroxyvitamin D status and the other demographic or clinical variables presented in Table 1, including sex, ethnicity, BMI z-score, age at diagnosis, weight, or HbA1c.

The distribution of 25-hydroxyvitamin D status among patients positive for specific autoantibodies is shown in Table 2. Among the five antibodies tested, only islet cell antibody (ICA) positivity was significantly associated with 25-hydroxyvitamin D status (p=0.04). Specifically, of the 41 patients who were ICA positive, a majority (56.1%) were 25-hydroxyvitamin D deficient, compared to 19.5% who were insufficient and 24.4% who were sufficient. No significant associations were found for patients positive for GAD, ZnT8, IA-2, or insulin antibodies.

Table 2

Distribution of 25-hydroxyvitamin D status among patients positive for specific autoantibodies.

Antibody positive (total n)Deficient, n (%)Insufficient, n (%)Sufficient, n (%)P-value
GAD (n=73)34 (46.6)25 (34.3)14 (19.2)0.47
ZnT8 (n=74)36 (48.7)22 (29.7)16 (21.6)0.31
ICA (n=41)23 (56.1)8 (19.5)10 (24.4) 0.04
IA-2 (n=48)27 (56.3)13 (27.1)8 (16.7)0.07
Insulin (n=44)21 (47.7)15 (34.1)8 (18.2)0.67

Data represents the distribution of 25-hydroxyvitamin D status for patients who tested positive for each antibody. Percentages are row percentages. GAD, Glutamic Acid Decarboxylase; ZnT8, Zinc Transporter 8; ICA, Islet Cell Antibody; IA-2, Islet Antigen-2.

Bold values indicate statistical significance (p < 0.05).

25-hydroxyvitamin D status was strongly associated with the biochemical markers of DKA severity (Table 3). Patients in the deficient group presented with significantly worse acidosis, having a lower median pH (7.2 vs. 7.3, p=0.002) and bicarbonate (9.5 vs. 20.0 mmol/L in the insufficient group, p=0.001), and a higher median beta-hydroxybutyrate level (6.6 vs. 2.8 mmol/L, p=0.02) compared to those with higher 25-hydroxyvitamin D levels. These findings were confirmed by correlation analysis, which showed a significant positive correlation between continuous 25-hydroxyvitamin D levels and both pH (rho=0.39, p<0.0001) and bicarbonate (rho=0.38, p=0.0001), and a significant negative correlation with BHB (rho=-0.32, p=0.003) (Table 4).

After adjusting for race, ethnicity, and insurance status, these correlations remained significant and strengthened to moderate for pH (rho=0.44, p<0.0001) and bicarbonate (rho=0.42, p<0.0001), while the correlation with BHB remained weak (rho=-0.28, p=0.01)(Table 4). Multivariable logistic regression revealed a significant association between 25-hydroxyvitamin D levels and DKA at presentation (p=0.03). Each one-unit increase in 25-hydroxyvitamin D was associated with a 6% decrease in the odds of presenting in DKA (OR: 0.94, 95% CI: 0.89-0.99), adjusted for race, ethnicity, and insurance.

Lastly, the Kruskal-Wallis test was used to assess the association between 25-hydroxyvitamin D levels and DKA severity (mild, moderate, severe). 25-hydroxyvitamin D levels were also significantly associated with DKA severity (Kruskal-Wallis test, p=0.01), with median levels decreasing with increasing DKA severity (Mild DKA: 21.6 ng/mL; Moderate DKA: 16.7 ng/mL; Severe DKA: 15.8 ng/mL) (Figure 1).

Table 3

Clinical outcomes by 25-hydroxyvitamin D status.

Outcome variable (median [Q1-Q3])Deficient (<20 ng/mL) (n=44)Insufficient (20 to 30 ng/mL) (n=33)Sufficient (>30 ng/mL) (n=22)P-value
Markers of DKA severity
 pH (n=97)7.2 [7.1 to 7.3]7.3 [7.3 to 7.4]7.3 [7.3 to 7.4] 0.002
 Bicarbonate (mmol/L) (n=99)9.5 [6.0 to 18.8]20.0 [10.0 to 22.0]18.0 [10.0 to 23.0] 0.001
 Beta-Hydroxybutyrate (mmol/L) (n=86)6.6 [3.9 to 8.5]2.8 [1.0 to 7.0]3.5 [1.2 to 6.3] 0.02
Beta-cell function
 Insulin Level (uU/mL) (n=57)3.8 [2.1 to 7.0]2.7 [1.7 to 5.5]2.3 [1.4 to 3.5]0.17
 C-Peptide Level (ng/mL) (n=68)0.7 [0.4 to 1.0]0.7 [0.5 to 1.3]0.7 [0.5 to 1.2]0.59

Bold values indicate statistical significance (p < 0.05).

Table 4

Correlation between markers of DKA severity and 25-hydroxyvitamin D levels.

VariableNrhop valueN*Rho*p-value*
pH at diagnosis970.39<.0001840.44<.0001
Bicarbonate (mmol/L)990.380.0001840.42<.0001
β hydroxybutyrate (mmol/L)86-0.320.00384-0.280.01

*Adjusted for Race, ethnicity and insurance.

Figure 1

25-hydroxyvitamin D levels are significantly lower in children with more severe diabetic ketoacidosis (DKA). The box-and-whisker plot shows the distribution of serum 25-hydroxyvitamin D levels (ng/mL) at presentation for patients with mild (n=17), moderate (n=17), and severe (n=19) DKA. Each box represents the median and interquartile range, with whiskers showing the min-to-max range. Individual data points are overlaid. A significant difference was found between the groups (Kruskal-Wallis test, p = 0.01).

Figure image at the original source: open the original paper. This file is not included in this text import.

No statistically significant correlations were found between 25-hydroxyvitamin D levels and HbA1c (rho=-0.08, p=0.45), insulin (rho=-0.23, p=0.08), or C-peptide (rho=0.16, p=0.20) (Table 5), even after adjusting for race, ethnicity, and insurance status. It’s important to note that insulin and C-peptide data were available for only 57 and 68 patients, respectively. For the 55 patients with complete data, after adjusting for race, ethnicity and insurance, the correlations remained statistically insignificant.

Table 5

Correlation between 25-hydroxyvitamin D levels and glycemic control & beta-cell function.

VariableNrhop-valueN*rho*p-value*
A1C99-0.080.45550.120.41
Insulin level57-0.230.0855-0.220.12
c-peptide level680.160.255-0.0020.99

*Adjusted for Race, ethnicity and insurance.

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusion

In this retrospective chart review of children newly diagnosed with T1DM, we found a significant association between 25-hydroxyvitamin D levels and DKA severity. Higher 25-hydroxyvitamin D levels correlated with less severe acidosis and lower odds of DKA presentation. This suggests a potential protective role of 25-hydroxyvitamin D against severe metabolic decompensation at T1DM onset. However, we found no significant association between 25-hydroxyvitamin D and markers of β-cell function or glycemic control at diagnosis. Further prospective studies are needed to confirm these findings, investigate the underlying mechanisms, and explore the potential clinical implications of optimizing 25-hydroxyvitamin D status in children at risk for or newly diagnosed with T1DM.

Source: Conclusion
Authors’ abstract

Introduction

This retrospective chart review investigated the relationship between 25-hydroxyvitamin D levels and the initial clinical and biochemical presentation of type 1 diabetes mellitus (T1DM) in children under 18 years of age, specifically: (1) presence or absence of diabetic ketoacidosis and the severity of diabetic ketoacidosis (DKA): among those with DKA, and (2) beta-cell function.

Methods

This study included 99 children with new-onset Type 1 Diabetes Mellitus (T1DM). Patients were diagnosed at our pediatric endocrinology practice at Northwell Health between June 2023 and February 2025. A diagnosis of T1DM at the time of presentation was confirmed by the presence of at least one positive diabetes-specific autoantibody, and all included patients were required to have a 25-hydroxyvitamin D level measured within two days of presentation. Data extracted from the electronic health record included demographics, 25-hydroxyvitamin D levels at diagnosis, hemoglobin A1C, measures of DKA severity (pH, bicarbonate, beta-hydroxybutyrate, and DKA severity categorization), and beta-cell function (insulin and C-peptide levels).

Statistical analyses included univariate tests, Spearman correlations, and multivariable logistic regression adjusting for race, ethnicity, and insurance status.

Results

Among 99 patients (mean age 10.3 ± 4.4 years, 50.5% female), 53.5% presented in DKA. After adjusting for race, ethnicity, and insurance status, higher 25-hydroxyvitamin D levels were significantly associated with less severe acidosis, showing moderate positive correlations with pH (rho=0.44, p<0.0001) and bicarbonate (rho=0.42, p<0.0001), and a weak negative correlation with beta-hydroxybutyrate (rho=-0.28, p=0.01), indicating higher 25-hydroxyvitamin D levels were associated with less severe acidosis. There was a significant association between 25-hydroxyvitamin D levels and presentation in DKA; each one-unit increase in 25-hydroxyvitamin D was associated with a 6% decrease in the odds of presenting in DKA (OR: 0.94, 95% CI: 0.89-0.99, p=0.03). 25-hydroxyvitamin D levels were significantly associated with DKA severity (p=0.01), with lower levels observed in patients with more severe DKA.

No significant association was found between 25-hydroxyvitamin D levels and HbA1c or markers of beta-cell function.

Discussion

These findings suggest a potential protective role of 25-hydroxyvitamin D against severe metabolic decompensation at T1DM onset, specifically relating to DKA, but not beta-cell function. Further research is needed to confirm these findings and explore the potential mechanisms and clinical implications.

Read the full paper

Introduction

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by pancreatic β-cell destruction and absolute insulin deficiency, with a rising global incidence that has prompted investigation into modifiable environmental influences such as 25-hydroxyvitamin D on disease risk and presentation (1, 2). Beyond its role in calcium homeostasis, 25-hydroxyvitamin D exerts immunomodulatory and anti-inflammatory effects that may be relevant to T1DM pathogenesis (1, 3). A high prevalence of 25-hydroxyvitamin D deficiency is reported in children with T1DM, but the link to T1DM development remains complex; some studies suggest early-life 25-hydroxyvitamin D sufficiency may be protective, while others find no clear association (3Not reported5).

At diagnosis, lower 25-hydroxyvitamin D is linked to increased DKA severity and poorer metabolic control including higher HbA1c and increased insulin needs (4, 6, 7). Children with DKA often have lower 25-hydroxyvitamin D levels, and acidosis severity correlates inversely with 25-hydroxyvitamin D status (6Not reported9). The relationship between 25-hydroxyvitamin D and β-cell function at diagnosis (measured by C-peptide and insulin) is less established. Some studies report associations with lower 25-hydroxyvitamin D and reduced C-peptide or higher insulin requirements, but interventional trials on vitamin D supplementation show inconsistent benefits (1, 10Not reported14).

This study examines the associations between 25-hydroxyvitamin D levels, the presence or absence of DKA as well as both DKA severity and markers of β-cell function (insulin and C-peptide) in newly diagnosed pediatric T1DM. Improved understanding of these relationships could inform risk stratification at presentation, guide early management strategies, and potentially support targeted interventions to optimize metabolic outcomes and preserve beta-cell function in this vulnerable population.

Materials and methods

Study design and population

This retrospective chart review included patients under the age of 18 years diagnosed with type 1 diabetes mellitus (T1DM) at Cohen Children’s Medical Center between June 2023 and February 2025. Patients were identified using an encrypted nursing log maintained at our Pediatric Endocrinology practice at Northwell Health in New Hyde Park, New York, which tracks all patients with newly diagnosed diabetes for diabetes education purposes. This log was used to identify potential T1DM cases. Patients with suspected type 2 diabetes were not included in the study. 146 patients with type 1 diabetes were identified.

Among them 43 patients without a documented 25-hydroxyvitamin D level within two days of presentation were excluded from data collection. 4 patients with suspected type 1 diabetes were also excluded due to the absence of diabetes autoantibodies. 99 patients with type 1 diabetes based on clinical presentation and at least one positive antibody were included in the study. The study aimed to investigate: 1) the association between 25-hydroxyvitamin D levels and initial presentation (presence or absence of DKA) as well as DKA severity at presentation (based on pH, bicarbonate and beta hydroxybutyrate levels); 2) the relationship between 25-hydroxyvitamin D levels and HbA1c at diagnosis; and 3) the relationship between 25-hydroxyvitamin D levels and markers of beta-cell function (insulin and C-peptide levels) at diagnosis.

Measurement of 25-hydroxyvitamin D is a standard component of the initial laboratory evaluation for new-onset T1DM at our institution. For this study, the inclusion criterion of a measurement within two days of presentation was established to ensure the level accurately reflected the patient’s status at the time of acute metabolic presentation.

Data collection

Demographic data (age, sex, race, ethnicity, language spoken, insurance status, weight, height for calculation of BMI z-scores and BMI z-scores), 25-hydroxyvitamin D levels, and clinical presentation data were extracted from the electronic health record (EHR) for all patients. 25-hydroxyvitamin D levels, measured at or around the time of T1DM diagnosis, were categorized as sufficient (>30 ng/mL), insufficient (20 to 30 ng/mL), and deficient (<20 ng/mL) for analysis. Clinical and biochemical presentation data included duration of symptoms, Hemoglobin A1c, diabetes autoantibody results, pH, bicarbonate, c-peptide levels, beta-hydroxybutyrate (BHB) levels, and the presence or absence of DKA.

DKA severity was categorized as mild (pH 7.2-7.29), moderate (pH 7.1-7.19), or severe (pH < 7.1) based on pH levels at presentation. Beta-cell function was assessed using insulin and C-peptide levels. Insulin levels drawn after the documented initiation of an intravenous insulin drip were excluded to avoid confounding from exogenous insulin. The timing and administration of potential subcutaneous insulin given prior to the drip could not be reliably determined retrospectively. Diabetes antibody testing included glutamic acid decarboxylase antibody (GAD), zinc transporter 8 antibody (ZnT8), islet cell antibody (ICA), islet IA-2 antigen antibody (IA-2) and insulin antibody.

Data analysis

Frequencies and proportions were calculated for categorical variables and means ± standard deviation (SD) or medians and interquartile ranges (IQR; Q1-Q3) were calculated for continuous variables, as appropriate. Univariate analyses were performed to compare demographic and clinical characteristics based on 25-hydroxyvitamin D levels (sufficient, insufficient, or deficient) using the Kruskal-Wallis test or ANOVA for continuous variables, and the Chi-square test or Fisher’s exact test for categorical variables, as appropriate. The Spearman rank correlation coefficient was reported between 25-hydroxyvitamin D levels and all continuous variables, along with the partial correlation coefficient adjusting for race, ethnicity, and insurance status.

Cohen’s guidelines were used to interpret the strength of the correlation. Multivariable logistic regression was utilized to evaluate the association between 25-hydroxyvitamin D levels and presentation in DKA, adjusting for race, ethnicity, and insurance status. The covariates were specified a priori. All analyses were conducted using available data and p-values < 0.05 were considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Data availability

The de-identified dataset supporting the conclusions of this article is available in the Supplementary Material.

Results

The baseline demographic and clinical characteristics of the 99 participants are summarized in Table 1. Demographic characteristics included a mean ± SD age of 10.3 ± 4.4 years, with 50.5% (n=50) female. Racial distribution was 21.2% Black (n=21), 40.4% (n=40) Asian/Native Hawaiian/Other, 38.4% (n=38) White, and the majority (70.7%, n=70) were not Hispanic or Latino. 55.6% (n=55) of all patients had commercial insurance. At presentation, 53.5% were in DKA (n=53), with a mean ± SD HbA1c of 11.9 ± 2.2%.

The median 25-hydroxyvitamin D level was 20.5 (IQR 16.0-28.8) ng/mL, and 44.4%(n=44) were 25-hydroxyvitamin D deficient (<20 ng/mL).

Table 1

Baseline demographic and clinical characteristics of subjects by 25-hydroxyvitamin D status.

VariableOverall (n=99)Deficient (<20 ng/mL) (n=44)Insufficient (20 to 30 ng/mL) (n=33)Sufficient (>30 ng/mL) (n=22)p value
Age, years (mean ± SD) 10.3 ± 4.410.3 ± 3.99.9 ± 4.59.1 ± 5.10.60
Weight, kg (median [IQR]) 36.1 [24.6 to 49.2]37.6 [29.0 to 49.5]38.8 [24.6 to 47.0]31.4 [21.2 to 57.4]0.76
BMI Z-score (mean ± SD)† -0.35 ± 1.55-0.17 ± 1.86-0.22 ± 1.31-0.88 ± 1.100.20
Sex, n (%) 0.86
 Female50 (50.5)23 (52.3)17 (51.5)10 (45.5)
 Male49 (49.5)21 (47.7)16 (48.5)12 (54.6)
Race, n (%) 0.02
 White38 (38.4)9 (20.5)16 (48.5)13 (59.1)
 Black21 (21.2)11 (25.0)6 (18.2)4 (18.2)
 Asian/Native
 Hawaiian/Other
40 (40.4)24 (54.5)11 (33.3)5 (22.7)
Ethnicity, n (%) 0.45
 Hispanic or Latino19 (19.2)12 (27.3)5 (15.2)2 (9.1)
 Not Hispanic or Latino70 (70.7)28 (63.6)25 (75.8)17 (77.3)
 Unknown10 (10.1)4 (9.1)3 (9.1)3 (13.6)
Type of Insurance* 0.0008
 Commercial55 (55.6)15 (34.9)25 (75.8)15 (68.2)
 Medicaid43 (43.4)28 (65.1)8 (24.2)7 (31.8)
Presence of DKA 0.002
 Yes53 (53.5)32 (72.7)11 (33.3)10 (45.5)
 No46 (46.5)12(27.3)22 (66.7)12 (54.6)
Hemoglobin A1c, % (mean ± SD)  11.9 ± 2.212.2 ± 2.011.4 ± 2.412.2 ± 2.20.24
25(OH)D, ng/mL (median [IQR] 20.5 [16.0 to 28.8]15.8 [14.5 to 17.8]23.3 [21.4 to 27.5]35.4 [31.7 to 41.3] <.0001

*Only 1 patient was uninsured and was excluded from this comparison.

†Data available for 96 patients.

Bold values indicate statistical significance (p < 0.05).

25-hydroxyvitamin D levels were significantly associated with several factors. White patients were more likely to have sufficient 25-hydroxyvitamin D levels, while Black/Asian/Native Hawaiian/Other patients were more likely to be deficient (p=0.02); 25-hydroxyvitamin D levels were significantly lower in patients with Medicaid compared to those with commercial insurance (p=0.0008). Patients presenting with DKA had significantly lower 25-hydroxyvitamin D levels (p=0.002), 72.7% of deficient patients presented in DKA, compared to 33.3% of insufficient and 45.5% of sufficient patients. No significant associations were found between 25-hydroxyvitamin D status and the other demographic or clinical variables presented in Table 1, including sex, ethnicity, BMI z-score, age at diagnosis, weight, or HbA1c.

The distribution of 25-hydroxyvitamin D status among patients positive for specific autoantibodies is shown in Table 2. Among the five antibodies tested, only islet cell antibody (ICA) positivity was significantly associated with 25-hydroxyvitamin D status (p=0.04). Specifically, of the 41 patients who were ICA positive, a majority (56.1%) were 25-hydroxyvitamin D deficient, compared to 19.5% who were insufficient and 24.4% who were sufficient. No significant associations were found for patients positive for GAD, ZnT8, IA-2, or insulin antibodies.

Table 2

Distribution of 25-hydroxyvitamin D status among patients positive for specific autoantibodies.

Antibody positive (total n)Deficient, n (%)Insufficient, n (%)Sufficient, n (%)P-value
GAD (n=73)34 (46.6)25 (34.3)14 (19.2)0.47
ZnT8 (n=74)36 (48.7)22 (29.7)16 (21.6)0.31
ICA (n=41)23 (56.1)8 (19.5)10 (24.4) 0.04
IA-2 (n=48)27 (56.3)13 (27.1)8 (16.7)0.07
Insulin (n=44)21 (47.7)15 (34.1)8 (18.2)0.67

Data represents the distribution of 25-hydroxyvitamin D status for patients who tested positive for each antibody. Percentages are row percentages. GAD, Glutamic Acid Decarboxylase; ZnT8, Zinc Transporter 8; ICA, Islet Cell Antibody; IA-2, Islet Antigen-2.

Bold values indicate statistical significance (p < 0.05).

25-hydroxyvitamin D status was strongly associated with the biochemical markers of DKA severity (Table 3). Patients in the deficient group presented with significantly worse acidosis, having a lower median pH (7.2 vs. 7.3, p=0.002) and bicarbonate (9.5 vs. 20.0 mmol/L in the insufficient group, p=0.001), and a higher median beta-hydroxybutyrate level (6.6 vs. 2.8 mmol/L, p=0.02) compared to those with higher 25-hydroxyvitamin D levels. These findings were confirmed by correlation analysis, which showed a significant positive correlation between continuous 25-hydroxyvitamin D levels and both pH (rho=0.39, p<0.0001) and bicarbonate (rho=0.38, p=0.0001), and a significant negative correlation with BHB (rho=-0.32, p=0.003) (Table 4).

After adjusting for race, ethnicity, and insurance status, these correlations remained significant and strengthened to moderate for pH (rho=0.44, p<0.0001) and bicarbonate (rho=0.42, p<0.0001), while the correlation with BHB remained weak (rho=-0.28, p=0.01)(Table 4). Multivariable logistic regression revealed a significant association between 25-hydroxyvitamin D levels and DKA at presentation (p=0.03). Each one-unit increase in 25-hydroxyvitamin D was associated with a 6% decrease in the odds of presenting in DKA (OR: 0.94, 95% CI: 0.89-0.99), adjusted for race, ethnicity, and insurance.

Lastly, the Kruskal-Wallis test was used to assess the association between 25-hydroxyvitamin D levels and DKA severity (mild, moderate, severe). 25-hydroxyvitamin D levels were also significantly associated with DKA severity (Kruskal-Wallis test, p=0.01), with median levels decreasing with increasing DKA severity (Mild DKA: 21.6 ng/mL; Moderate DKA: 16.7 ng/mL; Severe DKA: 15.8 ng/mL) (Figure 1).

Table 3

Clinical outcomes by 25-hydroxyvitamin D status.

Outcome variable (median [Q1-Q3])Deficient (<20 ng/mL) (n=44)Insufficient (20 to 30 ng/mL) (n=33)Sufficient (>30 ng/mL) (n=22)P-value
Markers of DKA severity
 pH (n=97)7.2 [7.1 to 7.3]7.3 [7.3 to 7.4]7.3 [7.3 to 7.4] 0.002
 Bicarbonate (mmol/L) (n=99)9.5 [6.0 to 18.8]20.0 [10.0 to 22.0]18.0 [10.0 to 23.0] 0.001
 Beta-Hydroxybutyrate (mmol/L) (n=86)6.6 [3.9 to 8.5]2.8 [1.0 to 7.0]3.5 [1.2 to 6.3] 0.02
Beta-cell function
 Insulin Level (uU/mL) (n=57)3.8 [2.1 to 7.0]2.7 [1.7 to 5.5]2.3 [1.4 to 3.5]0.17
 C-Peptide Level (ng/mL) (n=68)0.7 [0.4 to 1.0]0.7 [0.5 to 1.3]0.7 [0.5 to 1.2]0.59

Bold values indicate statistical significance (p < 0.05).

Table 4

Correlation between markers of DKA severity and 25-hydroxyvitamin D levels.

VariableNrhop valueN*Rho*p-value*
pH at diagnosis970.39<.0001840.44<.0001
Bicarbonate (mmol/L)990.380.0001840.42<.0001
β hydroxybutyrate (mmol/L)86-0.320.00384-0.280.01

*Adjusted for Race, ethnicity and insurance.

Figure 1

25-hydroxyvitamin D levels are significantly lower in children with more severe diabetic ketoacidosis (DKA). The box-and-whisker plot shows the distribution of serum 25-hydroxyvitamin D levels (ng/mL) at presentation for patients with mild (n=17), moderate (n=17), and severe (n=19) DKA. Each box represents the median and interquartile range, with whiskers showing the min-to-max range. Individual data points are overlaid. A significant difference was found between the groups (Kruskal-Wallis test, p = 0.01).

Figure image at the original source: open the original paper. This file is not included in this text import.

No statistically significant correlations were found between 25-hydroxyvitamin D levels and HbA1c (rho=-0.08, p=0.45), insulin (rho=-0.23, p=0.08), or C-peptide (rho=0.16, p=0.20) (Table 5), even after adjusting for race, ethnicity, and insurance status. It’s important to note that insulin and C-peptide data were available for only 57 and 68 patients, respectively. For the 55 patients with complete data, after adjusting for race, ethnicity and insurance, the correlations remained statistically insignificant.

Table 5

Correlation between 25-hydroxyvitamin D levels and glycemic control & beta-cell function.

VariableNrhop-valueN*rho*p-value*
A1C99-0.080.45550.120.41
Insulin level57-0.230.0855-0.220.12
c-peptide level680.160.255-0.0020.99

*Adjusted for Race, ethnicity and insurance.

Discussion

Our study investigated the relationship between 25-hydroxyvitamin D levels and the acuity of presentation and β-cell function in children newly diagnosed with type 1 diabetes. Our primary finding indicates a significant association between 25-hydroxyvitamin D levels and DKA presentation and severity. Higher 25-hydroxyvitamin D levels were associated with lower odds of DKA and less severe acidosis, as evidenced by the positive correlations with pH and bicarbonate, and the negative correlation with BHB. These findings persisted after adjusting for potential confounders, suggesting that 25-hydroxyvitamin D may play a protective role against severe metabolic decompensation at the onset of T1DM.

A critical consideration when interpreting our findings is the bidirectional relationship between acidosis and measured 25-hydroxyvitamin D levels, which complicates the determination of causality. While our data demonstrates that lower 25-hydroxyvitamin D levels are associated with more severe DKA, acidosis itself can transiently suppress measured 25-hydroxyvitamin D concentrations through multiple mechanisms (15, 16). Acute metabolic acidosis decreases 1-alpha-hydroxylase activity and increases 24-hydroxylase activity in the kidney, thereby reducing conversion of 25-hydroxyvitamin D to its active form (17).

Additionally, acidosis reduces vitamin D-binding protein (VDBP) levels, which in turn lowers total circulating 25-hydroxyvitamin D concentrations (6). Studies have shown that 25-hydroxyvitamin D levels increase by an average of 5 ng/mL following resolution of acidosis in children with new-onset T1DM, with bicarbonate levels correlating more strongly with 25-hydroxyvitamin D than pH (15, 16, 18). However, the persistence of low 25-hydroxyvitamin D levels after acidosis resolution in many patients suggests that true 25-hydroxyvitamin D deficiency, rather than solely acidosis-induced suppression, contributes to DKA severity (15).

This creates a potential vicious cycle: pre-existing 25-hydroxyvitamin D deficiency may predispose to more severe metabolic decompensation, while the resulting acidosis further suppresses measured 25-hydroxyvitamin D levels, exaggerating the apparent deficiency. Our study cannot definitively distinguish whether the observed low 25-hydroxyvitamin D levels represent chronic deficiency that contributed to DKA development, acute acidosis-induced suppression of 25-hydroxyvitamin D metabolism, or a combination of both mechanisms. Future prospective studies measuring 25-hydroxyvitamin D levels both at presentation and after complete metabolic stabilization, along with assessment of free and bioavailable 25-hydroxyvitamin D fractions, would help clarify this relationship.

This potential link between deficiency and DKA is biologically plausible, as our results align with previous research, suggesting a link between 25-hydroxyvitamin D deficiency and increased risk of autoimmune diseases, including T1DM (3, 6, 19). 25-hydroxyvitamin D has immunomodulatory properties, and its deficiency could contribute to a more aggressive autoimmune response, potentially leading to a more severe presentation of T1DM with DKA. There are several proposed mechanisms for this. First, 25-hydroxyvitamin D plays a role in modulating immune responses and inflammation.

Deficiency is linked to increased pro-inflammatory cytokine production (e.g., IFN-γ, TNF-α, IL-6, IL-1β), which may exacerbate the autoimmune destruction of pancreatic beta cells, leading to more rapid and severe insulin deficiency and thus more severe DKA at presentation (3, 4, 6, 20). This pathway is primarily about immune-mediated beta cell loss, not insulin resistance. Second, 25-hydroxyvitamin D deficiency in itself is linked to increased systemic inflammation, evidenced by higher circulating pro-inflammatory cytokines. This increased inflammatory state may worsen insulin resistance and accelerate the beta cell loss, leading to more severe DKA.

This mechanism is more about metabolic stress and insulin resistance, rather than direct autoimmune beta cell destruction. Finally, 25-hydroxyvitamin D is involved in maintaining calcium and phosphate homeostasis, which can be disrupted during acidosis, leading to worsening metabolic derangements in DKA. Children with lower 25-hydroxyvitamin D levels at diagnosis have worse glycemic control and higher insulin requirements which are risk factors for severe DKA (18).

Contrary to our hypothesis, we did not find a significant association between 25-hydroxyvitamin D levels and HbA1c or markers of β-cell function (insulin and C-peptide). This suggests that 25-hydroxyvitamin D’s potential protective effect may be specific to metabolic acidosis at diagnosis rather than overall glycemic control or β-cell preservation. It’s important to note the significant amount of missing data for insulin and C-peptide levels, which could have limited our ability to detect a true association. Previous studies have reported conflicting results, with some showing weak or short-term associations between 25-hydroxyvitamin D and glycemic markers, while others found no significant relationship, highlighting the diversity in study design, population, and timing of measurements (4, 21, 22).

This is consistent with currently published medical literature, which shows that 25-hydroxyvitamin D status at diagnosis does not reliably correlate with glycemic control or beta-cell reserve.

Our study also revealed significant associations between 25-hydroxyvitamin D levels and race. The observed disparity in 25-hydroxyvitamin D levels among racial and ethnic groups is primarily attributable to differences in skin pigmentation, genetic polymorphisms affecting 25-hydroxyvitamin D metabolism (23), and social determinants of health. Individuals with darker skin have higher melanin content, which reduces the skin’s ability to synthesize 25-hydroxyvitamin D from sunlight exposure. Melanin interferes with endogenous 25-hydroxyvitamin D production, leading to a higher prevalence of deficiency in these populations compared to White or Caucasian individuals, who generally have lighter skin and greater cutaneous vitamin D synthesis (24).

The significant correlation of 25-hydroxyvitamin D deficiency in patients receiving government assistance (Medicaid) compared to those with commercial insurance is likely related to socioeconomic factors such as reduced access to healthcare, delayed presentation for medical evaluation, and limited access to vitamin D-rich foods. Lower household income and food insecurity are associated with poorer diet quality and lower intake of vitamin D, while reduced healthcare access can delay both diagnosis and preventive care, increasing the risk of deficiency and more severe diabetic ketoacidosis at onset (24, 25).

Further research is warranted to explore these associations and potential disparities in 25-hydroxyvitamin D levels among different patient subgroups.

Our study showed an association between 25-hydroxyvitamin D levels and the presence of islet cell antibodies. This association was not found with other antibodies such as GAD, IA-2, ZnT8 and insulin antibodies. Islet cell antibodies (ICA) reflect a broad immune response against multiple islet cell antigens and are less specific than autoantibodies directed against defined antigens such as GAD, IA-2, ZnT8, or insulin. ICA positivity may indicate an earlier or more active stage of islet autoimmunity, and 25-hydroxyvitamin D deficiency: through its immunomodulatory effects: may preferentially influence the development of these broad-spectrum islet cell antibodies (2).

There is no evidence in literature to suggest there may be cross reactivity between these two assays (ICA and 25-hydroxyvitamin D).

Several limitations should be considered. The retrospective design introduces the potential for selection bias and limits our ability to establish causality. The relatively small sample size, especially for the analyses involving insulin and C-peptide, may have reduced statistical power. Specifically for the beta-cell function analysis, the significant amount of missing data for insulin and C-peptide, and the lack of systematically recorded concurrent glucose levels, limit the interpretation of these markers. Furthermore, 25-hydroxyvitamin D levels were measured at a single time point, which may not reflect long-term 25-hydroxyvitamin D status.

Importantly, acidosis at diagnosis can transiently lower serum 25-hydroxyvitamin D concentrations in type 1 diabetes patients, exaggerating differences with controls; adjusting for acidosis attenuates this effect (10). Additionally, due to the retrospective design, we could not account for a prior history of 25-hydroxyvitamin D deficiency or supplementation, which could have influenced the baseline levels observed at presentation. Finally, we did not systematically collect data on co-existing acute illnesses (e.g., infections), which could have independently influenced the severity of DKA at presentation.

Despite these limitations, our study provides valuable insights into the relationship between 25-hydroxyvitamin D and T1DM presentation. The association between 25-hydroxyvitamin D deficiency and DKA severity warrants further investigation in larger prospective studies. Future research should explore the mechanisms linking 25-hydroxyvitamin D and DKA, as well as the potential benefits of vitamin D supplementation in preventing severe metabolic complications in newly diagnosed T1DM patients. Additionally, studies should investigate the impact of socioeconomic factors and access to care on 25-hydroxyvitamin D levels in children at risk for T1DM.

Our findings suggest that optimizing 25-hydroxyvitamin D levels in children might be a potential avenue for mitigating the severity of T1DM presentation.

Conclusion

In this retrospective chart review of children newly diagnosed with T1DM, we found a significant association between 25-hydroxyvitamin D levels and DKA severity. Higher 25-hydroxyvitamin D levels correlated with less severe acidosis and lower odds of DKA presentation. This suggests a potential protective role of 25-hydroxyvitamin D against severe metabolic decompensation at T1DM onset. However, we found no significant association between 25-hydroxyvitamin D and markers of β-cell function or glycemic control at diagnosis. Further prospective studies are needed to confirm these findings, investigate the underlying mechanisms, and explore the potential clinical implications of optimizing 25-hydroxyvitamin D status in children at risk for or newly diagnosed with T1DM.

Edited by: Raú Calzada, National Institute of Pediatrics, Mexico

Reviewed by: David Baidal, University of Miami, United States

Yomna Ahmed Hosni, Cairo University, Egypt

Abbreviations: T1DM, Type 1 Diabetes Mellitus; DKA, Diabetic Ketoacidosis; BHB, Beta-hydroxybutyrate; EHR, Electronic Health Record; HbA1c, Hemoglobin A1c (Glycated Hemoglobin); CCMC, Cohen Children’s Medical Center, SD, Standard deviation; IQR, Interquartile range.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Northwell Health Institutional Review Board (IRB FWA 00002505). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because the study was determined to be exempt from full board review under federal regulation 45 CFR 46.104(d)(4)(iii) as a retrospective, secondary research use of identifiable private information.

A waiver of HIPAA authorization was also granted as per 45 CFR 164.512.

Author contributions

SI: Conceptualization, Data curation, Investigation, Methodology, Project administration, Visualization, Writing: original draft, Writing: review & editing. RS: Formal Analysis, Methodology, Writing: review & editing. SH: Conceptualization, Methodology, Resources, Supervision, Validation, Writing: review & editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Correction note

This article has been corrected with minor changes. These changes do not impact the scientific content of the article.

Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. To assist in editing the manuscript for grammar, clarity, and readability using Gemini Pro v2.5, and to aid in literature searching with OpenEvidence. All AI-generated outputs were critically reviewed, verified, and edited by the authors.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2026.1814563/full#supplementary-material

Supplement file at the original source: open the original paper. This file is not included in this text import.

References

1 Durá-Travé T Gallinas-Victoriano F . Type 1 diabetes mellitus and vitamin D . Int J Mol Sci . (2025 ) 26 (10 ):4593 . doi:  10.3390/ijms26104593 . PMID: 40429738 PMC12110774
2 Infante M Ricordi C Sanchez J Clare-Salzler MJ Padilla N Fuenmayor V . Influence of vitamin D on islet autoimmunity and beta-cell function in type 1 diabetes . Nutrients . (2019 ) 11 (9 ):2185 . doi:  10.3390/nu11092185 . PMID: 31514368 PMC6769474
3 Yu J Sharma P Girgis CM Gunton JE . Vitamin D and beta cells in type 1 diabetes: a systematic review . Int J Mol Sci . (2022 ) 23 (22 ):14434 . doi:  10.3390/ijms232214434 . PMID: 36430915 PMC9696701
4 Savastio S Cadario F Genoni G Bellomo G Bagnati M Secco G . Vitamin D deficiency and glycemic status in children and adolescents with type 1 diabetes mellitus . PloS One . (2016 ) 11 :e0162554. doi:  10.1371/journal.pone.0162554 . PMID: 27607348 PMC5015862
5 Wu J Atkins A Downes M Wei Z . Vitamin D in diabetes: uncovering the sunshine hormone's role in glucose metabolism and beyond . Nutrients . (2023 ) 15 (8 ):1997 . doi:  10.3390/nu15081997 . PMID: 37111216 PMC10142687
6 Choe Y Lee YJ Kim JH Lee K Shin CH Lee YA . Free, bioavailable 25-hydroxyvitamin D levels and their association with diabetic ketoacidosis in children with type 1 diabetes at diagnosis . Front Endocrinol (Lausanne) . (2022 ) 13 :997631. doi:  10.3389/fendo.2022.997631 . PMID: 36339444 PMC9631212
7 Savastio S Pozzi E Mancioppi V Boggio Sola V Carrera D Antoniotti V . Vitamin D repletion and AA/EPA intake in children with type 1 diabetes: influences on metabolic status . Nutrients . (2022 ) 14 (21 ):4603 . doi:  10.3390/nu14214603 . PMID: 36364863 PMC9655859
8 Yang X Chai M Lin M . Proportion of vitamin D deficiency in children/adolescents with type 1 diabetes: a systematic review and meta-analysis . BMC Pediatr . (2024 ) 24 :192 . doi:  10.1186/s12887-024-04683-5 . PMID: 38493103 PMC10943883
9 Nóvoa-Medina Y Barreiro-Bautista M Perdomo-Quinteiro M González-Martín JM Quinteiro-González S Domínguez Á . 25OHVitamin D levels in a Canarian pediatric population with and without type 1 diabetes: the role of acidosis . Nutrients . (2023 ) 15 (13 ):3067 . doi:  10.3390/nu15133067 . PMID: 37447392 PMC10346717
10 Sharma S Biswal N Bethou A Rajappa M Kumar S Vinayagam V . Does vitamin D supplementation improve glycaemic control in children with type 1 diabetes mellitus?: a randomized controlled trial . J Clin Diagn Res . (2017 ) 11 :Sc15: sc7. doi:  10.7860/jcdr/2017/27321.10645 . PMID: 29207798 PMC5713820
11 Nwosu BU Maranda L . The effects of vitamin D supplementation on hepatic dysfunction, vitamin D status, and glycemic control in children and adolescents with vitamin D deficiency and either type 1 or type 2 diabetes mellitus . PloS One . (2014 ) 9 :e99646. doi:  10.1371/journal.pone.0099646 . PMID: 24918447 PMC4053366
12 Nwosu BU Parajuli S Jasmin G Fleshman J Sharma RB Alonso LC . Ergocalciferol in new-onset type 1 diabetes: a randomized controlled trial . J Endocr Soc . (2022 ) 6 :bvab179. doi:  10.1210/jendso/bvab179 . PMID: 34913020 PMC8668202
13 Nascimento BF Moreira CFF da Fonseca ER Fedeszen PMK de Paula TP de Sena ASS . Effects of vitamin D supplementation on glycemic control of children and adolescents with type 1 diabetes mellitus: a systematic review . J Pediatr Endocrinol Metab . (2022 ) 35 :973 to 88. doi:  10.1515/jpem-2022-0044 . PMID: 35850934
14 Figueiredo Moreira CF Ferreira Peres WA Silva do Nascimento Braga J Proença da Fonseca AC Junior MC Luescher J . Effect of vitamin D supplementation on glycemic control in children and adolescents with type 1 diabetes mellitus: data from a controlled clinical trial . Diabetes Res Clin Pract . (2025 ) 224 :112210. doi:  10.1016/j.diabres.2025.112210 . PMID: 40319925
15 Devidayal Singh MK Sachdeva N Singhi S Attri SV Jayashree M . Vitamin D levels during and after resolution of ketoacidosis in children with new onset type 1 diabetes . Diabetes Med . (2013 ) 30 :829 to 34. doi:  10.1111/dme.12200 . PMID: 23692346
16 Huynh T Greer RM Nyunt O Bowling F Cowley D Leong GM . The association between ketoacidosis and 25(OH)-vitamin D levels at presentation in children with type 1 diabetes mellitus . Pediatr Diabetes . (2009 ) 10 :38Not reported43 . doi:  10.1111/j.1399-5448.2008.00439.x . PMID: 18761649
17 Cunningham J Bikle DD Avioli LV . Acute, but not chronic, metabolic acidosis disturbs 25-hydroxyvitamin D3 metabolism . Kidney Int . (1984 ) 25 :47Not reported52 . doi:  10.1038/ki.1984.7 . PMID: 6610073
18 Al-Zubeidi H Leon-Chi L Newfield RS . Low vitamin D level in pediatric patients with new onset type 1 diabetes is common, especially if in ketoacidosis . Pediatr Diabetes . (2016 ) 17 :592 to 8. doi:  10.1111/pedi.12342 . PMID: 26694737
19 Yang CY Leung PS Adamopoulos IE Gershwin ME . The implication of vitamin D and autoimmunity: a comprehensive review . Clin Rev Allergy Immunol . (2013 ) 45 :217 to 26. doi:  10.1007/s12016-013-8361-3 . PMID: 23359064 PMC6047889
20 Talaat IM Nasr A Alsulaimani AA Alghamdi H Alswat KA Almalki DM . Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes . J Endocrinol Invest . (2016 ) 39 :1425 to 34. doi:  10.1007/s40618-016-0514-9 . PMID: 27541155
21 Segovia-Ortí R Bennassar AB de Sotto-Esteban D Cortés PS . Vitamin D status is related to severity at onset of diabetes and worse glycemic control . J Pediatr Endocrinol Metab . (2020 ) 33 :1265 to 71. doi:  10.1515/jpem-2020-0149 . PMID: 32853168
22 Al Sawah S Compher CW Hanlon AL Lipman TH . 25-hydroxyvitamin D and glycemic control: a cross-sectional study of children and adolescents with type 1 diabetes . Diabetes Res Clin Pract . (2016 ) 115 :54 to 9. doi:  10.1016/j.diabres.2016.03.002 . PMID: 27242123
23 Powe CE Evans MK Wenger J Zonderman AB Berg AH Nalls M . Vitamin D: binding protein and vitamin D status of Black Americans and White Americans . N Engl J Med . (2013 ) 369 :1991Not reported2000 . doi:  10.1056/nejmoa1306357 . PMID: 24256378 PMC4030388
24 Demay MB Pittas AG Bikle DD Diab DL Kiely ME Lazaretti-Castro M . Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline . J Clin Endocrinol Metab . (2024 ) 109 :1907 to 47. doi:  10.1210/clinem/dgae290 . PMID: 38828931
25 Tolppanen AM Fraser A Fraser WD Lawlor DA . Risk factors for variation in 25-hydroxyvitamin D3 and D2 concentrations and vitamin D deficiency in children . J Clin Endocrinol Metab . (2012 ) 97 :1202 to 10. doi:  10.1210/jc.2011-2516 . PMID: 22278429
Publication and source details

Original title: 25-hydroxyvitamin D and the initial presentation of pediatric type 1 diabetes: associations with ketoacidosis severity and beta-cell function

Sofya Ilmer; Rubab Sohail; Sharon Hyman

Frontiers in Endocrinology · 2026

* Correspondence: Sharon Hyman, Shyman1@northwell.eduCopyright © 2026 Ilmer, Sohail and Hyman.2026Ilmer, Sohail and Hymanhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T10:44:18.759701+00:00

DOI: 10.3389/fendo.2026.1814563 · PMC13188172